Gilead’s remdesivir may benefit moderately ill COVID-19 patients but findings ‘uncertain’

/ / News

A study assessing Gilead Sciences Inc.’s experimental drug remdesivir in moderately ill hospitalized COVID-19 patients found that a shorter 5-day course of treatment was more effective than a 10-day regimen when compared to the standard of care at that time. The findings are from a randomized, open-label, Phase 3 trial and were published Friday in JAMA. The emergency use authorization granted to remdesivir is for severely ill COVID-19 patients; however, the drugmaker has announced plans to study different patient populations including the moderately ill and pregnant women who have been affected by the coronavirus. The study included 584 patients, with 193 on a 10-day course of treatment, 191 on a 5-day treatment plan, and 200 received standard care. This study “suggests modest clinical benefit for the 5-day course compared with standard care, although, as the authors acknowledge, the clinical importance of this finding is uncertain,” the authors of an accompanying editorial wrote in JAMA. “Some of the variation in results from the [randomized controlled trials] of remdesivir could be due to differences in study design.” Gilead’s stock has gained 1.7% year-to-date, while the S&P 500 is up 6.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.